VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | DESTINY-Breast04: practice-changing results for HER2-low breast cancer

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, speaks on the practice-changing findings from DESTINY-Breast04 (NCT03734029), a Phase III study that demonstrated improved survival of patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan compared to standard chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter